

1 Dalmore Drive,
Scoresby,
Victoria 3179
AUSTRALIA
T: +61 (0)3 9763-1287
F: +61 (0)3 9763-2817
www.generabiosystems.com

Tuesday 26 June 2018

**ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX: GBI)
CHANGE OF DIRECTOR’S INTEREST NOTICE - CORRECTION**

Genera Biosystems Limited (**‘Genera’**) attaches a corrected Change of Director’s Interest Notice for Richard Hannebery in relation to the Notice lodged on Friday 22 June 2018.

For further information please contact:


Mr Richard Hannebery
Chief Executive Officer
Genera Biosystems Limited
Telephone: +61 (0)3 9763 1287
www.generabiosystems.com.au

About Genera Biosystems : Genera Biosystems Limited (“GBI”) is an Australian Securities Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests.

Genera’s single-well high multiplex AmpaSand® testing platform can detect up to 125 target analytes in a single-well of a reaction plate. Unlike traditional real-time PCR approaches, AmpaSand® single-well multiplex tests when run on a seamlessly integrated flow cytometry and liquid handling system can provide unparalleled throughput capability and cost efficiency for high volume pathology laboratories qualitative molecular testing needs.¹

Genera manufactures products in its Australian Therapeutics Goods Administration certified manufacturing facility in Scoresby, Victoria, Australia.

¹ All ‘plate based’ Real Time PCR platforms can ‘multiplex’ up to 4 targets per well assuming 4 available channels of a Real Time PCR instrument. To multiplex greater than 4 target analytes in a test most platforms require use of additional wells of a plate to test for the additional target analytes. As such commercially, their multiplexing capability is restricted due to a direct trade-off with volume throughput per plate (96 or 384 well). Genera’s AmpaSand® technology facilitates the multiplexing of up to ~125 target analytes **in a single-well** of a plate. On a like for like basis depending on the number of target analytes detected in a multiplex assay Genera’s AmpaSand® technology facilitates > 4X relative volume throughput. High volume throughput is a key commercial consideration for all large pathology labs undertaking HPV and STI testing.



PapType[®], an ARTG listed and CE-marked MDx test, simultaneously detects and identifies 14 high-risk types of HPV and 2 low risk HPV types in a single-well. These high-risk HPV types are responsible for 99.7% of all cases of cervical cancer.

In addition to PapType[®], Genera has also commercialized and gained ARTG listing and CE mark for RTIplex[™], a single-well multiplex MDx that identifies 15 common upper respiratory tract pathogens, including Influenza A & B, as well as 10 other viral and 3 bacterial disease-causing microbial targets.

Genera's development pipeline includes a new 8-plex sexually transmitted infections panel that is expected to be available in the 2nd half of 2018, with plans to broaden the AmpaSand[®] test menu further to 6 highly competitive single-well multiplex MDx assays by 2019.

PapType[®], RTIplex[™], and the tests in development, employ the AmpaSand[®] biochemistry as well as Genera's proprietary ARTG listed and CE-IVD marked QPlots[™] automated analytical and reporting software that is compatible with most Laboratory Information Management Systems ('LIMS').

All the components of the Genera MDx system, including AmpaSand[®] and QPlots[™], have been optimized to run on Beckman Coulter's innovative CytoFLEX[™] flow cytometry system.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	GENERA BIOSYSTEMS LIMITED (ASX:GBI)
ABN	69 098 663 837

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Nicholas Hannebery
Date of last notice	24 May 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Indirect (1) Shares held by Robyn Gould (spouse of Richard Hannebery) Indirect (2) EG Capital Pty Limited, an entity in which Richard Hannebery has an interest Indirect (3) Silica Investments Pty Ltd, an entity in which Richard Hannebery has an interest
Date of change	19, 20, 21 June 2018

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p><u>Direct</u> 3,328,202 fully paid ordinary shares</p> <p>4,358,354 fully paid ordinary shares pursuant to Put/Call Option Deed and Call Option Deed</p> <p>1,000,000 performance rights vesting 31/12/17 subject to milestones</p> <p><u>Indirect (1)</u> 2,005,000 fully paid ordinary shares</p> <p><u>Indirect (2)</u> 823,228 fully paid ordinary shares</p> <p><u>Indirect (3)</u> 1,499,158 fully paid ordinary shares</p> <p>975,000 options exercisable at \$0.25 expiry 30/06/2019</p> <p>1,249,371 options exercisable at \$0.25 expiry 20/12/2020</p>
<p>Class</p>	<p>Fully paid ordinary shares</p>
<p>Number acquired</p>	<p>100,000</p>
<p>Number disposed</p>	<p>Nil</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>\$16,927</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<p><u>Direct</u> 3,428,202 fully paid ordinary shares</p> <p>4,358,354 fully paid ordinary shares pursuant to Put/Call Option Deed and Call Option Deed</p> <p>1,000,000 performance rights vesting 31/12/17 subject to milestones</p> <p><u>Indirect (1)</u> 2,005,000 fully paid ordinary shares</p> <p><u>Indirect (2)</u> 823,228 fully paid ordinary shares</p> <p><u>Indirect (3)</u> 1,499,158 fully paid ordinary shares</p> <p>975,000 options exercisable at \$0.25 expiry 30/06/2019</p> <p>1,249,371 options exercisable at \$0.25 expiry 20/12/2020</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market acquisition

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.